|Articles|April 1, 2011

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2011
  • Volume 0
  • Issue 0

Espacio Riesco

Espacio Riesco has adapted to the needs of pharma companies with the largest event space in Chile

The buzz of renewed pharmaceutical and healthcare sectors has extended beyond the direct activities of pharma companies and been spilt over to the service providers who are quickly adapting themselves to cater to the new and improved industry. A notable example of adaptation to the needs of pharma companies is that of the largest event space in the country, Espacio Riesco. Sergio Gutierrez, general manager of Espacio Riesco, describes that "we built this space in order to address the need for large congresses and conferences in the country and we began our operations by organizing the International Gynecology Congress at which we received more than 7,000 delegates. We are now counting with 180,000 square meters in total, out of which approximately 40,000 square meters are covered, which makes us the biggest multipurpose venue in the country. In this regard, we now have the capacity to accommodate 8,500 people for a sit-down dinner and not only for fairs and conferences." The conference center has its own in-house services for options such as catering and decoration, and is increasingly host to a number of pharmaceutical events. Gutierrez offers his vision for the future of Espacio Riesco by asserting that "we want to consolidate ourselves as the leader in the market of fairs, conferences, congresses and big corporate events."

Sergio Gutierrez, Espacio Riesco General Manager

Articles in this issue

over 15 years ago

iLogistica

over 15 years ago

Off-Label But On Point?

over 15 years ago

Pharm Exec Wins a Neal Award!

over 15 years ago

Restoring Public Trust in Pharma

over 15 years ago

Revisiting Reform

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.